Ashkon Software



LABD - S&P Biotech Bear -3X Direxion

S&P Biotech Bear -3X Direxion logoThe LABD ETF, or the S&P Biotech Bear -3X Direxion ETF, is an exchange-traded fund that seeks to provide daily investment results that correspond to three times the inverse of the daily performance of the S&P Biotechnology Select Industry Index. The index is designed to measure the performance of the biotechnology sub-industry based on the Global Industry Classification Standard (GICS).

As of the most recent report, the fund had total assets under management of approximately $31 million and an expense ratio of 1.13%. The fund is designed to be a leveraged ETF, which means that it is intended for short-term trading and is not suitable for long-term investors.

The LABD ETF is designed for investors who seek to profit from short-term declines in the biotechnology industry. The fund seeks to provide three times the inverse daily return of the S&P Biotechnology Select Industry Index, which means that if the index goes down by 1%, the fund aims to go up by 3%. However, it's important to note that leveraged ETFs are subject to significant risks and may experience losses that exceed the original investment, particularly over longer holding periods.

Overall, the LABD ETF may be appropriate for investors who have a high tolerance for risk and who seek to make short-term bets on the biotechnology industry. However, due to the risks associated with leveraged ETFs, investors should carefully consider their investment goals and risk tolerance before investing in the fund.




Copyright © 2000-2023, Ashkon Software LLC
Privacy Policy | Refund Policy | Disclaimer